infect
middl
east
respiratori
syndrom
coronaviru
merscov
could
asymptomat
caus
mild
influenzalik
ill
therefor
preval
merscov
infect
gener
popul
could
underestim
necessit
activ
surveil
determin
epidemiolog
import
asymptomat
case
aim
studi
evalu
perform
variou
serolog
assay
estim
seropreval
antimerscov
antibodi
highand
lowrisk
group
qatar
total
sampl
screen
includ
sampl
collect
healthi
blood
donor
bd
period
five
year
sampl
baselin
case
contact
cc
collect
individu
close
contact
three
posit
pcrconfirm
patient
cp
four
sampl
merscov
cp
initi
screen
use
antimerscov
igg
igg
kit
reveal
ten
reactiv
sampl
bd
one
cc
three
cp
sampl
cp
bd
also
reactiv
wholeviru
antimerscov
igg
n
igm
n
indirect
immunefluoresc
test
iift
pseudoparticl
neutral
test
ppnt
reactiv
sampl
cc
also
confirm
ppnt
surprisingli
one
thirteen
randomli
select
igg
bd
sampl
initi
screen
reactiv
igmiift
iggiift
subsequ
confirm
ppnt
igg
sampl
bd
exhibit
consider
reactiv
four
circul
human
coronavirus
crossreact
sar
report
sampl
cp
use
igg
igmiift
conclus
report
low
preval
antim
antibodi
gener
popul
coincid
low
number
report
case
time
studi
qatar
n
falseposit
result
observ
crossreact
merscov
circul
human
coronaviru
necessit
detail
evalu
avail
serolog
assay
infect
middl
east
respiratori
syndrom
coronaviru
merscov
could
asymptomat
caus
mild
influenzalik
ill
therefor
preval
merscov
infect
gener
popul
could
underestim
necessit
activ
surveil
determin
epidemiolog
import
asymptomat
case
aim
studi
evalu
perform
variou
serolog
assay
estim
seropreval
antimerscov
antibodi
highand
lowrisk
group
qatar
total
sampl
screen
includ
sampl
collect
healthi
blood
donor
bd
period
five
year
sampl
baselin
case
contact
cc
collect
individu
close
contact
three
posit
pcrconfirm
patient
cp
four
sampl
merscov
cp
initi
screen
use
antimerscov
igg
igg
kit
reveal
ten
reactiv
sampl
bd
one
cc
three
cp
sampl
cp
bd
also
reactiv
wholeviru
antimerscov
igg
n
igm
n
indirect
immunefluoresc
test
iift
pseudoparticl
neutral
test
ppnt
reactiv
sampl
cc
also
confirm
ppnt
surprisingli
one
thirteen
randomli
select
igg
bd
sampl
initi
screen
reactiv
igmiift
iggiift
subsequ
confirm
ppnt
igg
sampl
bd
exhibit
consider
reactiv
four
circul
human
coronavirus
crossreact
sar
report
sampl
cp
use
igg
igmiift
conclus
report
low
preval
antim
antibodi
gener
popul
coincid
low
number
report
case
time
studi
qatar
n
falseposit
result
observ
crossreact
merscov
circul
human
coronaviru
necessit
detail
evalu
avail
serolog
assay
middl
east
respiratori
syndrom
coronaviru
merscov
human
betacoronaviru
hcov
origin
identifi
kingdom
saudi
arabia
ksa
far
report
case
merscov
infect
countri
fatal
rate
n
merscovspecif
antibodi
wide
found
dromedari
camel
camelu
dromedariu
along
viral
shed
similar
virus
detect
human
accordingli
dromedari
consid
primari
sourc
merscov
transmiss
human
although
origin
sourc
viru
still
unknown
phylogenet
analysi
group
coronavirus
four
genera
alpha
beta
gamma
deltacoronavirus
bat
consid
natur
reservoir
virus
although
sarscov
close
relat
bat
cov
btcov
merscov
close
relat
pipistrellu
btcov
tylonycteri
btcov
serolog
antigen
relationship
virus
unclear
gener
coronavirus
across
subgroup
demonstr
low
level
crossreact
protein
limit
preserv
crossneutr
epitop
howev
studi
demonstr
crossreact
among
betacoronaviru
shown
mous
hyperimmun
sera
sarscov
harbor
low
level
neutral
activ
merscov
sera
sampl
sar
patient
demonstr
bind
neutral
activ
merscov
suggest
crossreact
within
subgroup
virus
follow
first
isol
sever
laboratori
diagnost
test
merscov
develop
molecular
test
rtpcr
sequenc
majorli
use
diagnos
merscov
infect
unit
state
center
diseas
control
prevent
cdc
limit
use
serolog
test
investig
surveil
set
diagnosi
establish
twophas
serolog
test
approach
detect
antim
antibodi
base
elisa
target
antigen
follow
wholeviru
igg
igm
iift
microneutr
test
confirm
microneutr
assay
highli
specif
gold
standard
measur
specif
neutral
antibodi
merscov
sera
sampl
nonetheless
compar
elisa
iift
microneutr
assay
requir
facil
avail
mani
place
laborintens
timeconsum
requir
least
day
result
avail
state
qatar
twentyon
case
report
includ
seven
death
interestingli
n
case
qatar
report
male
compar
one
femal
case
thirteen
mer
case
report
camel
farm
owner
worker
five
suspect
humantohuman
transmiss
three
nosocomi
infect
ministri
public
healthqatar
person
commun
qatar
first
nation
report
isol
full
genom
sequenc
merscov
camel
separ
studi
qatar
reusken
et
al
report
person
camel
contact
antibodi
reactiv
merscov
antigen
compar
zero
reactiv
control
noncas
contact
sampl
use
plaquereduct
neutral
test
merscov
antibodyreact
sampl
confirm
posit
due
uncertain
epidemiolog
pictur
merscov
among
qatar
popul
design
stage
serolog
surveil
studi
merscov
consist
initi
screen
antimerscov
igg
kit
follow
evalu
reactiv
sampl
use
wholeviru
indirect
immunofluoresc
assay
igmand
iggiift
ppnt
also
test
crossreact
igg
sampl
four
circul
human
coronavirus
use
elisa
iift
studi
target
three
group
lowrisk
group
constitut
sampl
obtain
blood
donor
bd
collect
period
five
year
ii
highrisk
group
repres
sampl
obtain
baselin
case
contact
cc
collect
individu
close
contact
confirm
case
acut
phase
first
week
iii
four
sampl
pcrconfirm
merscov
patient
cp
highrisk
group
defin
individu
direct
contact
confirm
case
either
work
hous
hospit
medic
staff
prior
symptom
develop
find
suggest
merscov
heavili
circul
among
popul
qatar
addit
presenc
antibodi
respons
human
coronavirus
result
falseposit
result
bind
assay
mandat
need
evalu
studi
current
avail
diagnost
serolog
assay
total
plasma
sampl
analyz
studi
sampl
distribut
follow
plasma
sampl
collect
bd
previou
studi
period
five
year
age
year
mean
age
year
plasma
sampl
collect
individu
cc
four
cp
age
year
mean
age
year
four
plasma
sampl
collect
cp
age
year
mean
age
cc
individu
repres
patient
famili
member
healthcar
worker
camel
farm
cowork
sampl
cc
collect
within
first
week
patient
admiss
hospit
studi
approv
qatar
universityirb
review
exempt
ququirb
initi
plasma
sampl
screen
presenc
antimerscov
subunit
igg
use
commerci
igg
kit
euroimmun
cat
ei
sinc
sampl
cc
collect
within
first
week
primari
case
identif
sampl
n
also
test
presenc
igm
antibodi
use
wholeviru
antimerscov
igm
iift
kit
igmiift
euroimmun
cat
fi
antimerscov
igmigg
iift
base
merscovinfect
eukaryot
cell
antimerscov
elisa
igg
purifi
antigen
merscov
recommend
borderlin
reactiv
sampl
test
presenc
antimerscov
antibodi
use
wholeviru
indirect
immunofluoresc
assay
igmand
iggiift
euroimmun
cat
fi
borderlin
reactiv
sampl
addit
randomli
select
igg
sampl
serv
neg
control
screen
inhous
protein
iifa
igg
institut
virolog
berlin
germani
describ
corman
et
al
order
reduc
possibl
crossreact
human
sera
full
mer
viru
antigen
present
vero
cell
wholeviru
iift
final
confirm
perform
use
pseudoparticl
neutral
test
ppnt
two
merscov
strain
emc
strain
genbank
jordan
strain
genbank
previous
describ
determin
crossreact
borderlin
reactiv
sampl
human
coronavirus
perform
use
commerci
avail
wholeviru
igmigg
iift
sarscov
euroimmun
cat
fi
gm
ii
prototyp
wholeviru
igg
iift
kit
euroimmun
prototyp
kit
iii
inhous
elisa
use
recombin
protein
sino
biolog
inc
catalog
iv
igg
humancov
institut
virolog
berlin
germani
demographi
characterist
profil
studi
popul
summar
tabl
initi
screen
antimerscov
antibodi
use
igg
reveal
reactiv
sampl
bd
three
borderlin
seven
posit
sampl
cc
respect
hand
cp
reactiv
igg
assay
figur
tabl
sinc
cc
sampl
collect
within
first
week
primari
case
identif
sampl
also
test
igmiift
neg
recommend
borderlin
reactiv
sampl
test
presenc
antimerscov
igg
use
wholeviru
recombin
r
analysi
wholeviru
iggiift
confirm
two
sampl
bd
well
three
sampl
cp
interestingli
none
bd
reactiv
sampl
test
posit
neither
ppnt
assay
posit
igg
cc
sampl
test
ppnt
posit
randomli
select
igg
neg
bd
sampl
also
neg
wholeviru
iggiift
tabl
determin
statu
infect
recent
versu
older
igg
reactiv
sampl
evalu
presenc
igm
antibodi
indic
recent
infect
use
wholeviru
iift
igmiift
one
margin
reactiv
cp
tabl
strikingli
one
randomli
select
igg
iggneg
bd
sampl
initi
screen
found
reactiv
igm
antibodi
use
igmiift
titer
posit
sampl
confirm
ppnt
titer
tabl
sampl
obtain
syrian
citizen
resid
qatar
discrep
result
obtain
differ
bind
assay
could
due
crossreact
virus
henc
evalu
crossreact
sampl
igg
antibodi
current
known
human
coronavirus
test
bd
sampl
includ
neg
control
initi
screen
exhibit
journal
immunolog
research
reactiv
least
human
coronavirus
sampl
reactiv
four
season
coronavirus
tabl
reactiv
also
high
neg
control
initi
screen
reach
partial
data
shown
tabl
none
test
bd
sampl
reactiv
sarscov
use
wholeviru
igg
similarli
sampl
cp
also
highli
reactiv
human
coronavirus
interestingli
two
cp
sampl
consider
reactiv
sarscov
titer
use
igg
tabl
discrep
crossreact
also
observ
among
differ
serolog
test
human
coronavirus
exampl
one
sampl
cp
test
neg
wholeviru
iift
igg
reactiv
recombin
protein
viru
use
similar
assay
similarli
two
sampl
cp
show
reactiv
sarscov
igg
wherea
sampl
higher
antibodi
titer
react
wholeviru
iggiift
assay
sampl
cp
react
spike
protein
two
sampl
yield
posit
reaction
igg
tabl
journal
immunolog
research
qatar
report
rel
low
number
mer
case
comparison
neighbor
countri
despit
fact
merscov
continu
circul
camel
absenc
clear
epidemiolog
view
merscov
present
compar
serolog
studi
preval
antim
coronaviru
antibodi
highand
lowrisk
group
qatar
follow
recommend
run
initi
screen
igg
antibodi
use
reactiv
sampl
confirm
full
viru
igg
follow
ppnt
combin
result
differ
serolog
test
indic
low
presenc
neutral
antimerscov
antibodi
gener
popul
qatar
rate
increas
highrisk
group
cc
result
reveal
interest
observ
first
confirm
posit
sampl
bd
group
accident
detect
test
randomli
select
neg
sampl
origin
select
serv
neg
control
initi
screen
use
igm
respons
screen
igm
typic
done
similar
studi
mandat
develop
util
assay
measur
class
antibodi
screen
process
nonetheless
result
coincid
low
number
report
case
qatar
n
compar
neighbor
countri
saudi
arabia
highest
number
report
mer
case
worldwid
n
similar
studi
use
similar
approach
saudi
arabia
confirm
posit
antim
antibodi
gener
popul
number
slightli
higher
observ
studi
howev
low
number
posit
sampl
studi
prevent
signific
statist
analysi
anoth
interest
observ
seroposit
cc
sampl
although
sampl
collect
within
first
week
primari
case
identif
one
sampl
posit
igg
igm
antibodi
indic
previou
exposur
viru
also
journal
immunolog
research
confirm
infect
merscov
go
unnot
surveil
studi
shall
done
systemat
includ
screen
igm
igg
respons
similar
observ
gener
popul
rate
seroposit
highrisk
group
cc
analysi
lower
observ
saudi
arabia
sever
factor
could
explain
differ
studi
includ
differ
sampl
size
well
demograph
livestock
popul
countri
one
four
mer
cp
sampl
show
antibodi
respons
use
whole
viru
assay
sampl
collect
acut
infect
phase
explain
absenc
antimerscov
igg
respons
recent
studi
south
korea
indic
humor
respons
merscov
measur
bind
neutral
assay
wean
rapidli
one
year
infect
becom
undetect
show
mild
ill
upon
infect
anoth
studi
korea
shown
none
asymptomat
infect
individu
show
seroconvers
howev
seroconvers
rate
gradual
increas
increas
diseas
sever
reach
symptomat
infect
without
pneumonia
pneumonia
without
respiratori
failur
pneumonia
progress
respiratori
failur
respect
studi
indic
human
humor
immun
respons
merscov
complic
phenomenon
requir
investig
impli
infect
rate
merscov
middl
east
could
underestim
fatal
rate
associ
merscov
infect
like
overestim
observ
studi
result
signific
falseposit
result
sampl
posit
assay
posit
wholeviru
iggiift
null
confirm
ppnt
similarli
test
sampl
saudi
arabia
studi
posit
posit
wholeviru
iift
confirm
neutral
assay
result
indic
crossreact
merscov
human
coronavirus
test
employ
sever
bind
assay
test
reactiv
sampl
five
known
human
coronavirus
name
sar
cov
interestingli
mersreact
sampl
first
screen
well
randomli
select
neg
control
sampl
crossreact
least
season
human
virus
none
crossreact
sarscov
hand
two
cp
sampl
crossreact
sarscov
intermedi
titer
accordingli
clear
human
coronaviru
induc
crossreact
merscov
mandat
investig
also
observ
discrep
crossreact
use
differ
assay
iift
sensit
full
viru
counterpart
could
due
higher
concentr
specif
protein
first
assay
also
ensur
use
defin
regent
purifi
protein
develop
screen
assay
hand
crossreact
sar
merscov
report
earlier
studi
chan
et
al
indic
sar
patient
signific
bind
antibodi
titer
use
iift
seven
antim
emc
neutral
antibodi
low
titer
significantli
correl
studi
bioinformat
analysi
demonstr
signific
bcell
epitop
overlap
heptad
region
spike
protein
two
virus
acknowledg
limit
studi
includ
use
elisa
procedur
screen
antimerscov
igg
respons
domin
male
femal
versu
nonqatari
qatari
versu
well
screen
onetim
point
find
affirm
use
neutral
assay
lower
extent
spike
proteinspecif
iift
confirmatori
test
consid
high
crossreact
among
differ
human
coronavirus
find
similar
recent
report
drosten
et
al
show
excess
igg
detect
antim
igg
confirm
iggiift
assay
result
indic
high
discrep
differ
assay
avail
market
screen
antimerscov
antibodi
elisabas
assay
seem
prone
produc
falseposit
result
result
iift
alway
confirm
neutral
test
avail
elisa
assay
util
protein
part
whole
protein
mani
case
well
character
use
use
affin
purifi
structur
defin
protein
might
reliabl
produc
accur
result
recent
determin
sever
ectodomain
structur
mani
coronavirus
instrument
design
better
immunogen
also
util
develop
specif
screen
assay
lastli
investig
possibl
merscov
transmiss
blood
transfus
asymptomat
donor
also
assess
though
case
report
far
evid
blood
transfus
sourc
merscov
infect
data
use
support
find
studi
avail
correspond
author
upon
request
find
achiev
herein
sole
respons
author
